Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMG6W5)

• Drug Name: F-50040 Drug Info
• Synonyms: Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMMG6W5

Molecule-Related Drug Atlas

Drug(s) Targeting MART-1 melanoma antigen (MLANA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[4]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[5]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[6]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[7]

Drug(s) Targeting Toll-like receptor 2 (TLR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[8]
MCS-18	DMX4U0B	Autoimmune diabetes	5A10	Phase 2	[9]
OPN-305	DM1IBRT	Myelodysplastic syndrome	2A37	Phase 2	[10]
MALP-2S	DMBZ68C	Pancreatic cancer	2C10	Phase 1/2	[11]
Lipoteichoic acid	DMEMRW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
S-(Dimethylarsenic)Cysteine	DMSCHL0	Discovery agent	N.A.	Investigative	[14]
CBLB-612	DMCFR8U	Radiation syndrome	NF00	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MART-1 melanoma antigen (MLANA)	TT362RB	MAR1_HUMAN	Modulator	[2]
Toll-like receptor 2 (TLR2)	TTY7ZHS	TLR2_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016041)
• [2] Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
• [3] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [4] National Cancer Institute Drug Dictionary (drug id 685201).
• [5] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
• [8] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [9] The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
• [10] Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
• [11] Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
• [12] Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
• [13] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [14] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752).